The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.
Patients with beta-thalassemia who will receive conventional thalassemia management.
Both genders.
Age ≥ 18 years old.
Patients with familial hypercholesterolemia or history of premature atherosclerosis.
Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke.
Patients with severe renal dysfunction.
Patients with severe hepatic dysfunction.